Abstract
Respiratory biologics are FDA approved for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). However, there is limited data regarding patterns of utilization and efficacy of respiratory biologics in aspirin-exacerbated respiratory disease (AERD), a chronic disease characterized by asthma, CRSwNP, and hypersensitivity reactions to cyclooxygenase-1 inhibitors. We sought to characterize the patient experience with respiratory biologics for the treatment of AERD.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
